Promise of factor Xa inhibition in acute coronary syndromes

Leong Lee, Derek Chew

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)


    Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.

    Original languageEnglish
    Pages (from-to)40-48
    Number of pages9
    JournalCurrent Cardiology Reports
    Issue number1
    Publication statusPublished - Feb 2012


    • Acute coronary syndrome
    • Apixaban
    • Enoxaparin
    • Factor Xa
    • Factor Xa inhibition
    • Fondaparinux
    • Heparin
    • Low molecular weight heparin
    • NSTEMI
    • Otamixaban
    • Rivaroxaban
    • STEMI
    • Unfractionated heparin
    • Unstable angina


    Dive into the research topics of 'Promise of factor Xa inhibition in acute coronary syndromes'. Together they form a unique fingerprint.

    Cite this